Bavencio Intravenous 200 mg Special Drug Use - results Survey (Curatively unresectable Merkel cell carcinoma)

Bavencio Intravenous 200 mg Special Drug Use - results Survey (Curatively unresectable Merkel cell carcinoma) - Bavencio Special Drug Use-results Survey (Merkel cell carcinoma)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038827

Enrollment

Registered

2019-12-10

Start date

2017-11-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Curatively unresectable Merkel cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who received at least one dose of this drug during the enrollment period from November 22, 2017 to November 2, 2022.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The safety parameters (occurrence of adverse drug reactions and serious adverse events, etc.)	—

Secondary

Measure	Time frame
Efficacy (response rate)	—

Countries

Japan

Contacts

Public ContactTaito Ito

Merck Biopharma Co., Ltd. PMS Planning & Strategy, Medical Department

taito.ito@merckgroup.com03-6756-0805

Outcome results